Saxenda vs Wegovy vs Zepbound: GLP-1 Injection Comparison
Saxenda, Wegovy and Zepbound are FDA-approved injectable obesity medicines, but they use different active ingredients, schedules and mechanisms. Newer options generally produce greater average loss, while Saxenda can remain useful when coverage or tolerability favors it.
Comparison at a glance
| Feature | Saxenda | Wegovy | Zepbound |
|---|---|---|---|
| Ingredient | Liraglutide | Semaglutide | Tirzepatide |
| Schedule | Daily injection | Weekly injection | Weekly injection |
| Mechanism | GLP-1 | GLP-1 | GIP/GLP-1 |
| Average trial pattern | Lower than newer weekly options | Strong | Generally highest among these in major studies |
| Special point | Longer clinical experience | Product-specific cardiovascular indication | Defined OSA indication |
Why Saxenda may still be chosen
Daily dosing may be less convenient, but the shorter action can be useful when tolerability is uncertain. Some insurers may cover one brand but exclude another. Previous response to liraglutide also matters.
Choosing a weekly option
Wegovy may be favored for its semaglutide evidence and available oral pathway. Zepbound may be favored when greater average loss or the OSA indication is relevant. W8MD reviews the person rather than selecting solely from a chart.
W8MD supports not only weight loss but also protein planning, sleep evaluation, side-effect management and prevention of regain. Individual results vary.
What to expect from a W8MD medication evaluation
The first step is not choosing a brand from an advertisement. W8MD reviews weight history, previous diets and prescriptions, medication allergies, blood pressure, pulse, sleep symptoms, glucose status, relevant laboratory results, cardiovascular history, gastrointestinal symptoms, kidney and liver concerns, pregnancy plans and current medicines. This helps identify contraindications and realistic alternatives.
The treatment plan can include a lower-cost traditional prescription, an FDA-approved incretin medicine, structured nutrition, meal replacements, a medically supervised very-low-calorie diet for selected patients, home sleep-apnea testing or a combination of services. Follow-up assesses appetite response, adverse effects, hydration, protein intake, bowel symptoms, blood pressure, muscle preservation and progress toward health-centered goals. A dose is not increased simply because a calendar date arrives.
Affordable W8MD treatment pathways
Semaglutide
From $29.99/week when insurance is accepted for qualifying visits. Self-pay pathways start from $59.99/week.
Tirzepatide
From $45/week when insurance is accepted for qualifying visits. Self-pay pathways start from $69.99/week.
Traditional prescriptions
Phentermine, topiramate, Qsymia, Contrave, diethylpropion, phendimetrazine and orlistat may be considered when clinically appropriate.
Pricing notice: Starting prices are not guaranteed for every patient or dose. Visit, medication, laboratory, supply, shipping, copay, deductible and dose costs may be separate. Insurance coverage of a visit does not guarantee pharmacy coverage.
Medication safety and supervision
Prescription obesity treatment requires an individualized evaluation. Common considerations include pregnancy, cardiovascular disease, blood pressure, kidney and liver health, gastrointestinal disease, gallbladder and pancreatic history, glaucoma, mental health, diabetes medicines, controlled-substance risk and drug interactions. Product-specific FDA labeling controls.
Frequently asked questions
Which is injected daily?
Saxenda.
Which produced the greatest average loss?
Zepbound generally produced the highest averages in major separate trials.
Can these medicines be combined?
No. Combining GLP-1 or related incretin therapies is not recommended.
Related Philadelphia and W8MD resources
Philadelphia services
WikiMD encyclopedia
How W8MD Philadelphia can help
W8MD physicians have more than 20 years of clinical experience and compare medical conditions, contraindications, previous attempts, appetite patterns, sleep, cultural food preferences, insurance coverage, patient preferences and long-term cost. Care can include medication, structured nutrition, a medically supervised VLCD for selected patients, sleep-apnea evaluation, muscle-preservation planning and maintenance.
1718 Welsh Road, 2nd Floor, Suite C, Philadelphia, PA 19115
Phone: 215-676-2334
Serving Northeast Philadelphia, Bucks County, Montgomery County, Delaware County, nearby Pennsylvania communities and South Jersey, subject to clinical and licensure requirements.
Contact W8MD Philadelphia
Use this form for nonurgent appointment and service questions.